Business
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and
About this update from Oculis Holding Ag
[{"type":"text","content":"The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn Loftsson. OPTIREACH is behind Oculis’ lead candidate OCS-01, currently in Phase 3 development in patients with Diabetic Macular Edema (DME) and for the treatment of inflammation and pain following cataract surgery.The revolutionary and proprietary OPTIREACH technology enables the formulation of topical eye drops to reach the back-of-the-eye at therapeutic concentration, as shown in the recent positive and robust clinical trial results from the DIAMOND program with OCS-01 in DME.The award also recognizes the successful journey of Oculis internationally and in broadening its portfolio with other novel and promising drug candidates for eye diseases including OCS-02, a topical anti-TNF alpha for ocular inflammation and OCS-05, a neuroprotective candidate for neuro-ophthalmology diseases, both in clinical development. ZUG, Switzerland and BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it has won the 2023 Knowledge Award from the Icelandic Association of Business and Economics. Oculis has received the Knowledge Award this year for its research developing Oculis’ OPTIREACH solubilizing formulation technology, by Professors Stefánsson and Loftsson, Oculis’ co-founded, which took place in Oculis’ laboratory in Iceland. OPTIREACH was created to solve the limitations of conventional eye drops, including the limited solubility of drugs in eye drop formulations, quick removal by tear flow and inability to deliver drugs to the retina. The technology is one of the proprietary platforms underpinning Oculis’ highly differentiated pipeline of innovative product candidates, including lead candidate OCS-01, a novel, high concentration, preservative-free, topical formulation of dexamethasone, currently in Phase 3 development in patients with diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery. The technology is also being leverage in other ongoing formulation projects. The award also recognized Oculis’ successful journey internationally and in broadening its portfolio which includes two additional p...